VIRAL. Development and characterization of a high purity human factor VIII concentrate, treated with two specific viral inactivation methods (Fanhdi®);Desarrollo y caracterización de un concentrado de factor VIII humano de alta pureza, sometido a dos tratamientos específicos de inactivación viral (Fanhdi®)

Sangre

Volumn 41, Issue 2, 1996, Pages 125-130

  Ristol, Pedro ^a   Gensana, Marta ^a   Fernández, Jesús ^a   Massot, Marta ^a   Bhattacharya, Prabir ^b   Jorquera, Juan I ^a  

^a Instituto Grifols   (Spain)

^b Grifols SA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DETERGENT; HEPARIN; MACROGOL DERIVATIVE; ORGANOPHOSPHATE; PLASMA PROTEIN; POLYSORBATE; SOLVENT; TRIBUTYL PHOSPHATE; BLOOD CLOTTING FACTOR 8 CONCENTRATE;

AFFINITY CHROMATOGRAPHY; ARTICLE; BLOOD; BLOOD CLOTTING; COLD; DRUG EFFECT; HEAT; HEMOPHILIA A; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PRECIPITATION; VIROLOGY; VIRUS; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG STABILITY; TECHNIQUE; VIRUS INACTIVATION;

BLOOD; BLOOD COAGULATION; BLOOD PROTEINS; CHROMATOGRAPHY, AFFINITY; COLD; DETERGENTS; FACTOR VIII; HEAT; HEMOPHILIA A; HEPARIN; HUMANS; PHOSPHORIC ACID ESTERS; POLYETHYLENE GLYCOLS; POLYSORBATES; PRECIPITATION; SOLVENTS; VIRUSES;

EID: 0030113683     PISSN: 00364355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993; 64: 197-203.
2. Mannucci PM Effects of Factor VIII concentrates on the immune system of patients with hemophilia. Thromb Haemost 1995; 74: 437-439.
3. Arrieta R, Aznar JA, Magallón M, Padilla A, Serrano MA, Tusell JM, et al. Recomendaciones sobre la elección de concentrados plasmáticos de factor VIII en la hemofiliaA.Biol Clin Hematol 1993; 15 213- 218.
4. Ruggeri ZM, Ware J, The structure and function of von Willebrand factor. Thromb Haemost 1992; 67: 594-599.
5. Piet MPJ. Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990; 30: 591-598.
6. Hardisty RM. MacPherson JC. A one-step factor VIII (anti- hemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh 1962: 7: 215-228.
7. Rosen S. Assay of factor VIII: C with a chromogenic substrate. Scand J Haematol (Suppl) 1984; 40: 139-145.
8. MacFarlane DE, Stibbe J, Kirby EP, Zucker MB. Grant R A, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308.
9. Schneppenheim R. Plendl H. Budde U. Luminography - an alternative assay for detection of von Willebrand factor multimers. Thromb Haemost 1988; 60: 133-136
10. Ruggeri ZM, Zimmerman TS The complex multimeric composition of Factor VIH/von Willebrand factor. Blood 1981; 57: 1140-1143.
11. Told H, Suomela H. An optimized assay for prckallicrcm activador activity in human plasma products Thromb Res 1982; 27: 35-44.
12. Mannucci PM, Lattuuda A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994; 83: 3018- 3027.
13. Meyer D. Girma JP. von Willebrand factor: structure and function. Thromb Haemosl 1993;70 99-104.
14. Giddings JC. Molecular genetics and immunoanalysis in blood coagulation. Nueva York: Ellis Horwood, 1988.
15. Fijnvandraat K, Peters M, ten Gate JW. Inter-individual variation in half-life of transfused FVIII concentrate is associated with pre-in fusion vWF Ag levels. Thromb Haemost 1995; 73: 1017 (abstract).
16. Greeno E, Boelsen R, Chase B, Key N. Von Willebrand factor proteolysis as an additional hemostatic defect in hemophilia patients with liver disease. Blood 1994; 84 (Suppl. I): 198a (abstract).
17. Amano K, Arai M, Koshihara K, Suzuki T, Kagawa K, Nishida Y, et al. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex. Ain J Hematol 1995; 49: 310-317.
18. Shima M, Nakai H, Scandella D, Tanaka I, Sawamoto Y, Kamisue, et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Blood 1995; 86 (Suppl. I): 190a (abstract).
19. Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl) phosphate and sodium cholate. Lancet 1986; i: 706-710.
20. Horowitz B, Bonomo R, Prince AM. Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79: 826-831.
21. Skidmore SJ, Pasi KJ, Mawson SJ, Williams MD, Hill FGH Serological evidence that dry heating of clotting factor concentrates prevents transmission ofnon-A, non-B hepatitis J Med Virol 1990; 30: 50-52.
22. McLaughlin LF, MacGregor IR. MacGregor MC, Pepper DS, Prowse CV. Assessment of methods for detection of neoantigens in blood products. Thromb Haemost 1995; 73: 1211 (abstract).
23. Bhattacharya P, Motokubota T, Bunch C. Characteristics and viral safety of alphanate and its heat-treated version. Thromb Haemost 1995; 73: 1013 (Abstract).